Table 2.

Prior corticosteroid use by steroid-refractory status

	GVHD progression after 3 d* (n = 19)	No improvement in GVHD after 7 d* (n = 30)	New GVHD† (n = 8)	Taper intolerant (n = 14)	Total (N = 71)
Dose of corticosteroid at enrollment, mg/d
Mean (SD)	179.9 (58.1)	169.9 (63.5)	114.2 (55.0)	124.1 (45.9)	157.3 (62.2)
Median (range)	180.0 (81.3-300.0)	168.8 (62.5-300.0)	109.4 (50.0-212.5)	125.0 (60.0-200.0)	156.3 (50.0-300.0)
Days on corticosteroids before enrollment
Mean (SD)	31.6 (52.8)	32.2 (54.9)	20.6 (23.5)	28.9 (23.4)	30.1 (46.2)
Median (range)	14.0 (6.0-224.0)	13.0 (6.0-285.0)	13.5 (3.0-75.0)	21.0 (6.0-85.0)	15.0 (3.0-285.0)

^*After primary treatment with methylprednisolone at least 2 mg/kg per day.

^†In another organ in patients who previously received corticosteroids (≥1 mg/kg per day methylprednisolone) for skin or skin plus upper GI GVHD.